Back to Results

Castle Biosciences Inc (CSTL)

Featured in High-Momentum Stocks

Castle Biosciences, Inc. is a molecular diagnostics company focused on tests used in the assessment and management of several medical conditions, including dermatologic cancers, Barrett’s esophagus, atopic dermatitis, and uveal melanoma. Its product portfolio includes DecisionDx-Melanoma, TissueCypher, AdvanceAD-Tx, DecisionDx-SCC, MyPath Melanoma, and DecisionDx-UM. These tests are used in dermatology and gastroenterology settings and are designed to support clinical decision-making through risk assessment and diagnosis-related insights. Castle Biosciences was incorporated in 2007 and is headquartered in Friendswood, Texas. The company’s common stock is listed on NASDAQ under the ticker CSTL.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-CSTL
$32.87
-3.9% Downside
Fair
$46.70
36.5% Upside
Undervalued
Great
0.0%
2.2x
2.9x
1.045 B
814.6 M
3.2%
89.0%
7.9
2.5%
Valuation • Fair Value

Castle Biosciences Inc (NASDAQ-CSTL) Fair Value by Valuation Model

Review the available estimates for Castle Biosciences Inc (NASDAQ-CSTL), including DCF Fair Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$32.87

Estimated downside of 3.9% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$38.30

Discounted cash flow valuation reference.

EPV Fair Value

$26.23

Earnings power value estimate.

Comps Fair Value

$33.07

Comparable-company valuation reference.

Analyst Price Target

$46.70

Analysts imply upside of 36.5%.

How to read these valuation models

Use the 6 available valuation references for Castle Biosciences Inc (NASDAQ-CSTL) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Castle Biosciences Inc (NASDAQ-CSTL)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

357.3 M

Current operating scale indicator.

Revenue Forecast

373.7 M

Forward revenue estimate.

EBITDA

-16.516 M

Current operating profitability reference.

EBITDA Forecast

11.6 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Castle Biosciences Inc (NASDAQ-CSTL) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Castle Biosciences Inc (NASDAQ-CSTL)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

-4.15

No elevated caution signal from this screen.

Altman Z-Score

7.9

Relatively strong balance-sheet zone.

FCF / Net Income

2.5%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Castle Biosciences Inc (NASDAQ-CSTL). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for Castle Biosciences Inc (NASDAQ-CSTL)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Castle Biosciences Inc (NASDAQ-CSTL). No upcoming dividend amount or event date is currently available.

Stock Forecast • Technical Outlook

Castle Biosciences Inc (NASDAQ-CSTL) Stock Forecast & Technical Outlook

Review Castle Biosciences Inc (NASDAQ-CSTL) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Castle Biosciences Inc (NASDAQ-CSTL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Castle Biosciences Inc (NASDAQ-CSTL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Castle Biosciences Inc (NASDAQ-CSTL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Castle Biosciences Inc (NASDAQ-CSTL) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Castle Biosciences Inc (NASDAQ-CSTL) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Castle Biosciences Inc (NASDAQ-CSTL)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Castle Biosciences Inc (NASDAQ-CSTL) has a Strong Buy consensus, with 10 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 10
Hold 0
Sell 0
FAQ • Fast Investor Answers

Castle Biosciences Inc (NASDAQ-CSTL) Stock FAQ

Data-supported answers about Castle Biosciences Inc (NASDAQ-CSTL), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$32.87
Estimated downside 3.9%
Valuation Rating
Overvalued
Estimated downside of 3.9%
Analyst Target
$46.70
Implied upside 36.5%
Financial Health
Great
Current financial-health read

The current fair value estimate for Castle Biosciences Inc (NASDAQ-CSTL) is $32.87. This implies an estimated downside of 3.9% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 3.9% versus the current market price.

The available analyst price target for Castle Biosciences Inc (NASDAQ-CSTL) is $46.70. The analyst target implies estimated upside of 36.5%.

The current financial health read for Castle Biosciences Inc (NASDAQ-CSTL) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for Castle Biosciences Inc (NASDAQ-CSTL).

The current market capitalization listed for Castle Biosciences Inc is 1.045 B.

The current enterprise value listed for Castle Biosciences Inc is 814.6 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Castle Biosciences Inc is NASDAQ-CSTL, and the stock is listed on NASDAQ.

Castle Biosciences Inc (NASDAQ-CSTL) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Castle Biosciences Inc is 3.2%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Castle Biosciences Inc is 89.0%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Providers & Services Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

UNH NYSE Unitedhealth Group Fair Value Undervalued Market Cap 354.6 B
MCK NYSE McKesson Corporation Fair Value Fair Market Cap 123.8 B
HCA NYSE HCA Holdings Inc Fair Value Fair Market Cap 106 B
CVS NYSE CVS Health Corp Fair Value Bargain Market Cap 104.1 B
ELV NYSE Elevance Health Inc Fair Value Fair Market Cap 93.336 B
CI NYSE Cigna Corp Fair Value Bargain Market Cap 79.663 B
COR NYSE Cencora Inc Fair Value Undervalued Market Cap 64.82 B
CAH NYSE Cardinal Health Inc Fair Value Fair Market Cap 62.016 B
HUM NYSE Humana Inc Fair Value Fair Market Cap 49.448 B
CNC NYSE Centene Corp Fair Value Fair Market Cap 36.719 B
LH NYSE Labcorp Holdings Inc Fair Value Fair Market Cap 29.5 B
DGX NYSE Quest Diagnostics Incorporated Fair Value Fair Market Cap 28.026 B
THC NYSE Tenet Healthcare Corporation Fair Value Fair Market Cap 22.799 B
GH NASDAQ Guardant Health Inc Fair Value Overvalued Market Cap 20.59 B
EHC NYSE Encompass Health Corp Fair Value Fair Market Cap 13.862 B
BTSG NASDAQ Brightspring Health Services Inc Fair Value Fair Market Cap 13.723 B
FMS NYSE Fresenius Medical Care Corporation Fair Value Undervalued Market Cap 12.325 B
DVA NYSE DaVita HealthCare Partners Inc Fair Value Fair Market Cap 12.258 B
UHS NYSE Universal Health Services Inc Fair Value Undervalued Market Cap 11.704 B
MOH NYSE Molina Healthcare Inc Fair Value Fair Market Cap 11.285 B